Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19978912 | 0.92 | NFKB1 (0.34) | NFKB1NFKB2RELA | |
| SCHEMBL26621759 | 0.82 | NFKB1 (0.37) | NFKB1NFKB2RELA | |
| SCHEMBL19973017 | 0.82 | — | — | |
| SCHEMBL22506790 | 0.82 | — | — | |
| SCHEMBL19978927 | 0.81 | NR1H2 (0.35) | NFKB1NFKB2RELA | |
| SCHEMBL19978905 | 0.76 | NR1H2 (0.30) | — | |
| SCHEMBL19972951 | 0.74 | NFKB1 (0.37) | NFKB1NFKB2RELA | |
| SCHEMBL19972948 | 0.74 | NFKB1 (0.37) | NFKB1NFKB2RELA | |
| SCHEMBL19972949 | 0.74 | NFKB1 (0.37) | NFKB1NFKB2RELA | |
| SCHEMBL16558945 | 0.71 | NFKB1 (0.33) | NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023212343-A1 | DURLOBACTAM CRYSTALLINE FORMS | ENTASIS THERAPEUTICS LIMITED (GB) | 2023-11-02 | — | — | WO | disclosed |
| US-10800778-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2020-10-13 | — | — | US | disclosed |
| EP-3512851-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | Entasis Therapeutics Limited (GB) | 2019-07-24 | — | — | EP | disclosed |
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| WO-2018053215-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | LCT, MGAM, MRPL21 | NFKB1 1068/4885NFKB2 1786/4885RELA 670/4885 |
| US-10800778-B2 | Beta-lactamase inhibitor compounds | LCT, MGAM, MRPL21 | NFKB1 1068/4885NFKB2 1786/4885RELA 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.